The risk of cancer in people with diabetes and chronic kidney disease

Germaine Wong; Sophia Zoungas; Serigne Lo; John Chalmers; Alan Cass; Bruce Neal; Mark Woodward; Vlado Perkovic; Paul Glasziou; Bryan Williams; Kirsten Howard; Jeremy R. Chapman; Jonathan C. Craig

doi:10.1093/ndt/gfs022

The risk of cancer in people with diabetes and chronic kidney disease

Germaine Wong, Sophia Zoungas, Serigne Lo, John Chalmers, Alan Cass, Bruce Neal, Mark Woodward, Vlado Perkovic, Paul Glasziou, Bryan Williams, Kirsten Howard, Jeremy R. Chapman, Jonathan C. Craig

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).

Original language	English (US)
Pages (from-to)	3337-3344
Number of pages	8
Journal	Nephrology Dialysis Transplantation
Volume	27
Issue number	8
DOIs	https://doi.org/10.1093/ndt/gfs022
State	Published - Aug 2012
Externally published	Yes

Keywords

CKD
cancer
cumulative incidence
diabetes

ASJC Scopus subject areas

Nephrology
Transplantation

Access to Document

10.1093/ndt/gfs022

Cite this

@article{eb9821ad50ec4ca2a4668c98ca905a78,

title = "The risk of cancer in people with diabetes and chronic kidney disease",

abstract = "Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).",

keywords = "CKD, cancer, cumulative incidence, diabetes",

author = "Germaine Wong and Sophia Zoungas and Serigne Lo and John Chalmers and Alan Cass and Bruce Neal and Mark Woodward and Vlado Perkovic and Paul Glasziou and Bryan Williams and Kirsten Howard and Chapman, {Jeremy R.} and Craig, {Jonathan C.}",

note = "Funding Information: Role of the funding source. ADVANCE was funded by grants from Servier and the National Health and Medical Research Council of Australia (211086 and 358395). The funding organizations had no role in the design or conduct of the study, collection, management, analysis or interpretation of data or preparation of the manuscript.",

year = "2012",

month = aug,

doi = "10.1093/ndt/gfs022",

language = "English (US)",

volume = "27",

pages = "3337--3344",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - The risk of cancer in people with diabetes and chronic kidney disease

AU - Wong, Germaine

AU - Zoungas, Sophia

AU - Lo, Serigne

AU - Chalmers, John

AU - Cass, Alan

AU - Neal, Bruce

AU - Woodward, Mark

AU - Perkovic, Vlado

AU - Glasziou, Paul

AU - Williams, Bryan

AU - Howard, Kirsten

AU - Chapman, Jeremy R.

AU - Craig, Jonathan C.

N1 - Funding Information: Role of the funding source. ADVANCE was funded by grants from Servier and the National Health and Medical Research Council of Australia (211086 and 358395). The funding organizations had no role in the design or conduct of the study, collection, management, analysis or interpretation of data or preparation of the manuscript.

PY - 2012/8

Y1 - 2012/8

N2 - Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).

AB - Background. Diabetes and chronic kidney disease (CKD) are both associated with an increased risk of cancer but it is unclear whether diabetes complicated by CKD further augments an individual's cancer risk. The aim of our study was to determine the association of CKD [defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min] with the overall and site-specific risks of incident cancers among individuals with Type 2 diabetes. Methods. Cox proportional hazard regression models and competing risk analyses were used to examine the univariate and multivariate adjusted associations between reduced kidney function and the overall and site-specific risks of cancer in participants enrolled in the Action in Diabetes and Vascular disease: Preterax and Diamicron MR controlled evaluation (ADVANCE) trial. Results. Over a median follow-up of 5.0 years, 700 malignant neoplasms occurred in the 11 140 (6.4) participants. There was no increase in overall cancer risk [adjusted hazard ratio: 1.07 (95 confidence interval: 0.891.29, P 0.50)] or site-specific cancer risk for individuals with CKD (defined as eGFR < 60 mL/min) compared to those without CKD at baseline. These results were robust to multiple methods and thresholds used to estimate CKD. Conclusion. sMild to moderate CKD does not increase the risk of cancer in people with Type 2 diabetes. ADVANCE is registered with ClincalTrial.gov (number NCT00145925).

KW - CKD

KW - cancer

KW - cumulative incidence

KW - diabetes

UR - http://www.scopus.com/inward/record.url?scp=84864629526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864629526&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfs022

DO - 10.1093/ndt/gfs022

M3 - Article

C2 - 22357699

AN - SCOPUS:84864629526

SN - 0931-0509

VL - 27

SP - 3337

EP - 3344

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 8

ER -

The risk of cancer in people with diabetes and chronic kidney disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this